EFFECT OF BREAST CANCER THERAPY ON SERUM LEVEL OF ATPBINDING CASSETTE.

Cancer is a disease of cellular growth that is uncontrolled. The gold standard for treating metastatic breast cancer is chemotherapy. Chemotherapy failure, however, is still a serious obstacle to effective breast cancer chemotherapy due to multidrug resistance. Although, evidence has been given that ATP-Binding Cassette (ABC) carriers have excessive overexpression, therapeutic studies aimed at ABCb1 in order to reverse drug resistance have been failing to impart resistance to cytototoxic and targeted chemical therapies through decreasing intracellular accumulation. The serum ABCA1 levels, as well as age and BMI, were measured. Blood samples were taken from 60 women who had been diagnosed with breast cancer before beginning treatment and after completing chemotherapy or hormonal therapy. Age and BMI matched 60 healthy women selected as control. Serum ABCA1 showed A significant decrease in patients group when compared to control group (p<0.05). The mean of the ABCA1 level in patients without taking any therapy, having chemotherapy and patients having chemotherapy plus hormonal therapy were 0.53, 0.40 and 0.28 ng/Ml, respectively. Difference in the mean ABCA1 level according to cancer therapy were significantly decrease, patients having chemotherapy and patients having chemotherapy plus hormonal therapy (p value > 0.05 and p value > 0.01), respectively, comparing to patients group without taking any therapy. The results showed that no correlation between ABCA1 with age and BMI in the breast cancer and control groups. As our knowledge no previous studies showed to effect of therapy on serum ABCA1 level. Overall, current available result suggests effector of cancer therapy on ABCA1. [ABSTRACT FROM AUTHOR]